《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2014年 > 9期

沙格列汀对2型糖尿病慢性肾脏疾病患者同型半胱氨酸、高敏C反应蛋白及尿白蛋白肌酐比值水平影响的研究

来自:中国糖尿病杂志  编辑: 陈宽林 华云峰 王健 周青|点击数:|2014-09-24

 糖尿病慢性肾脏疾病

  【摘要】 目的 探讨沙格列汀对糖尿病慢性肾脏疾病(CKD)患者血清同型半胱氨酸(Hcy)、高敏C反应蛋白(hsC-RP)及UAlb/Cr水平的影响。 方法 将82例CKD患者分为两组,治疗组在原治疗基础上予沙格列汀5 mg,1次/d,对照组原治疗不变,比较两组治疗前后指标变化。 结果 治疗前两组间各指标比较差异均无统计学意义。治疗组治疗前后各指标比较差异均有统计学意义(P<0.01),对照组Hcy、hsC-RP和UAlb/Cr治疗后较治疗前升高(P<0.01)。两组治疗前后SBP、平均动脉压、HDL-C、LDL-C、Hcy、hsC-RP和UAlb/Cr差值比较差异有统计学意义(P<0.01)。单因素相关性分析显示,两组治疗前后UAlb/Cr与Hcy、hsC-RP均呈正相关(P<0.01)。 结论 血清Hcy、hsC-RP与CKD存在相关性,沙格列汀可有效降低Hcy、hsC-RP和UAlb/Cr水平,下调BP、体重,调节HDL-C、LDL-C代谢,对糖尿病肾脏有保护作用。

  【关键词】沙格列汀;糖尿病慢性肾脏疾病;同型半胱氨酸;高敏C反应蛋白;尿白蛋白肌酐比值

  【Abstract】Objective To investigate the effect of saxagliptin on chronic kidney disease (CKD) in diabetes, through an observation on the changes in the serum levels of homocysteiune (Hcy), high sensitivity C-reactive protein (hsC-RP) and UAlb/Cr. Methods 82 cases of CKD were divided into two groups, 57 patients with CKD were treated with 5 mg saxagliptin once a day besides privious regimes, and the other 25 patients with CKD were treated with the previcious regimens. The levels of general data and biochemical characteristics were detected before and after treatment. Results The differences of all indices between two groups before treatment were not significant respectively. The differences of all indices after treatment were significant respectively in treatment group(P<0.01), the differences of Hcy, hsC-RP and UAlb/Cr after treatment were significant respectively in control group(P<0.01). There were significant differences of different values of SBP, mean blood pressure, HDL-C, LDL-C, Hcy, hsC-RP and UAlb/Cr between two groups. The correlations between UAlb/Cr and Hcy, UAlb/Cr and hsC-RP in two groups were positively significant respectively (P<0.01). Conclusion Serum Hcy and hsC-RP were high-positively correlated with CKD, administrating of saxagliptin for the CKD is effective in improving UAlb/Cr by downregulating Hcy, hsC-RP, lowing blood pressure, BMI and LDL-C at the same time.

  【Key words】Saxagliptin;Chronic kidney disease (CKD) in diabetes;Homocysteiune (Hcy);High sensitivity C-reactive protein (hsC-RP);Urinary albumin/creatine ratio (UAlb/Cr)

上一篇: 2型糖尿病慢性肾脏疾病患者血浆心钠素水平变化及其临床意义 下一篇: 艾塞那肽改善2型糖尿病合并非酒精性脂肪性肝病的疗效观察